Your browser doesn't support javascript.
loading
Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: Results from the ROSEL multicenter randomized trial.
Louie, Alexander V; van Werkhoven, Erik; Chen, Hanbo; Smit, Egbert F; Paul, Marinus A; Widder, Joachim; Groen, Harry J M; van den Borne, Ben E E M; De Jaeger, Katrien; Slotman, Ben J; Senan, Suresh.
Afiliação
  • Louie AV; Department of Radiation Oncology, VU University Medical Center, Amsterdam, Netherlands; Department of Radiation Oncology, London Regional Cancer Program, Canada. Electronic address: dr.alexlouie@gmail.com.
  • van Werkhoven E; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Chen H; Department of Radiation Oncology, London Regional Cancer Program, Canada.
  • Smit EF; Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, Netherlands.
  • Paul MA; Department of Cardiothoracic Surgery, VU University Medical Center, Amsterdam, Netherlands.
  • Widder J; Department of Radiation Oncology, University Medical Center Groningen, Netherlands.
  • Groen HJ; Department of Pulmonary Diseases, University Medical Center Groningen, Netherlands.
  • van den Borne BE; Department of Pulmonary Diseases, Catharina Hospital, Eindhoven, Netherlands.
  • De Jaeger K; Department of Radiation Oncology, Catharina Hospital, Eindhoven, Netherlands.
  • Slotman BJ; Department of Radiation Oncology, VU University Medical Center, Amsterdam, Netherlands.
  • Senan S; Department of Radiation Oncology, VU University Medical Center, Amsterdam, Netherlands.
Radiother Oncol ; 117(1): 44-8, 2015 Oct.
Article em En | MEDLINE | ID: mdl-26492839
We report quality of life and indirect costs from patient reported outcomes from the ROSEL randomized control trial comparing stereotactic ablative radiotherapy (SABR, also known as stereotactic body radiotherapy or SBRT) versus surgical resection for medically operable stage IA non-small cell lung cancer. ROSEL closed prematurely after accruing and randomizing 22 patients. This exploratory analysis found the global health related quality of life and indirect costs to be significantly favorable and cheaper, with SABR.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Clinical_trials Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Radiother Oncol Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Clinical_trials Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Radiother Oncol Ano de publicação: 2015 Tipo de documento: Article